The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Public ClinicalTrials.gov record NCT03659136. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main objective of the trial is to assess the efficacy of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.
Study identification
- NCT ID
- NCT03659136
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 28, 2018 (Actual)
- Primary completion
- Aug 30, 2021 (Actual)
- Completion
- May 11, 2022 (Actual)
- Last update posted
- Feb 24, 2025
2018 – 2022
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer and Research Centers | Chandler | Arizona | 85224 | — |
| Cancer Treatment Centers of America at Western Regional Medical Center | Goodyear | Arizona | 85338 | — |
| Beverly Hills Cancer Center | Beverly Hills | California | 90211 | — |
| University of California San Francisco | San Francisco | California | 94158 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| University Cancer and Blood Center | Athens | Georgia | 30607 | — |
| Hematology Oncology of Indiana | Indianapolis | Indiana | 46260 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| HCA MidAmerica Division, Inc. | Kansas City | Missouri | 64132 | — |
| Hematology Oncology Associates of Rockland | Nyack | New York | 10960 | — |
| Southwestern Regional Medical Center | Tulsa | Oklahoma | 74133 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| Utah Cancer Specialists Cancer Center | Salt Lake City | Utah | 84106 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03659136, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2025 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03659136 live on ClinicalTrials.gov.